AsclepiX Therapeutics
US-based AsclepiX Therapeutics innovates retinal disease and cancer treatments through novel peptide development.
Founded
2011US-based AsclepiX Therapeutics innovates retinal disease and cancer treatments through novel peptide development.
AsclepiX Therapeutics, founded in Baltimore, United States, is dedicated to transforming the treatment of retinal diseases and cancer. The company's core mission is to design, develop, and deliver novel peptide-based therapies that inhibit key disease pathways. By leveraging pioneering computational biology methods, AsclepiX aims to empower patients and their families globally with groundbreaking treatments that offer improved quality of life.
Notable affiliated individuals include leading experts in the fields of ophthalmology and oncology. The company has attracted significant investment from prominent venture capital firms, underscoring its potential impact. Key achievements include the rapid clinical development of their peptide drug candidates, which have shown promise in preclinical studies. AsclepiX Therapeutics is poised to make a substantial impact on the healthcare industry by offering innovative solutions for challenging diseases.
Companies similar to AsclepiX Therapeutics include Peptilogics, Apexian Pharmaceuticals, Neurexis Therapeutics and Peel Therapeutics.
AsclepiX Therapeutics was founded in 2011.
AsclepiX Therapeutics' headquarters is located in Baltimore, MD, US.
AsclepiX Therapeutics' most recent funding round was for $10M (USD) in July 2023.
As of Jul 26, 2023, AsclepiX Therapeutics has disclosed funding of $50M (USD). Undisclosed round amounts are excluded.
AsclepiX Therapeutics has 16 employees as of Feb 5, 2024.
Peel Therapeutics
peeltx.com
